Autolus Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Autolus Therapeutics is Chris Itin, benoemd in Mar2016, heeft een ambtstermijn van 10.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.70M, bestaande uit 25% salaris en 75% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.42% van de aandelen van het bedrijf, ter waarde $ 2.40M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 2.9 jaar.
Belangrijke informatie
Chris Itin
Algemeen directeur
US$2.7m
Totale compensatie
| Percentage CEO-salaris | 24.98% |
| Dienstverband CEO | 10.4yrs |
| Eigendom CEO | 0.4% |
| Management gemiddelde ambtstermijn | 3yrs |
| Gemiddelde ambtstermijn bestuur | 2.9yrs |
Recente managementupdates
Recent updates
Analyse-artikel • Aug 14
Autolus Therapeutics plc (NASDAQ:AUTL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Autolus Therapeutics plc ( NASDAQ:AUTL ) just released its latest quarterly results and things are looking bullish. The...
Narratiefupdate • Jun 23
AUTL: Early Treatment Demand And 2026 Margin Shift Could Drive Repricing
Autolus Therapeutics' analyst price targets have shifted, with one firm raising its view to $10 from $9 as analysts point to growing U.S. demand for Aucatyzl and a positive early launch in the UK. Analyst Commentary Recent research on Autolus Therapeutics highlights a mix of optimism and caution as analysts react to the early commercial progress of Aucatyzl and update their valuation work.Narratiefupdate • Jun 05
AUTL: Early Demand Trends And Profit Outlook Set Up Potential Repricing
Analysts have nudged their average price target on Autolus Therapeutics to around $10, reflecting updated views on Aucatyzl U.S. demand and an early positive read on the UK launch, even as differing research opinions partly offset one another. Analyst Commentary Street research around Autolus Therapeutics is split, with bullish analysts focusing on early commercial traction for Aucatyzl and more cautious voices questioning how much of that optimism is already reflected in valuation.
Narratiefupdate • May 18
AUTL: Early Commercial Traction And Cost Actions Will Support A Brighter Outlook
Analysts have adjusted their fair value estimate for Autolus Therapeutics to $11.00 from $13.00, citing updated assumptions around revenue growth, profitability, and future P/E, along with recent shifts in Street price targets following the Q1 report and Aucatyzl launch trends in the U.S. and UK. Analyst Commentary Recent Street commentary reflects a mix of optimism and recalibration around Autolus Therapeutics, with bullish analysts pointing to early commercial trends for Aucatyzl as a key driver for their views on valuation and execution.Narratiefupdate • May 03
AUTL: Rebased Profit Assumptions Set Stage For Future Upside Execution
Analysts have reduced their price targets on Autolus Therapeutics by $2 to $3, citing updated assumptions on discount rates, profit margins, and future P/E levels that temper prior expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the updated discount rates and profit margin assumptions as a reset that can make future execution milestones more impactful for valuation, rather than relying on aggressive prior models.Narratiefupdate • Apr 18
AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Analysts have modestly lifted their fair value estimate for Autolus Therapeutics from $8.79 to $8.81, tying the change to updated assumptions for discount rates, revenue growth, profit margins, and future P/E, along with recent price target revisions from the Street. Analyst Commentary Recent Street research has focused on recalibrating price targets for Autolus Therapeutics, which feeds directly into the modest change in fair value.Narratiefupdate • Mar 31
AUTL: Lower 2026 Sales Guidance Will Still Support Upside Potential
Analysts have trimmed their price targets on Autolus Therapeutics by $2 to $3 following updated 2026 Aucatzyl sales guidance of $120M to $135M, as well as a recalibration of revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research notes highlight a mixed but focused view on Autolus Therapeutics, centered on execution against updated Aucatzyl sales guidance, cost structure, and how these flow through to valuation assumptions.Seeking Alpha • Mar 27
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Summary Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues and a shift to positive gross margin, with AUTL's cash runway projected into Q4 2027. Key catalysts include pediatric ALL Phase 2 data (2027) and initial MS autoimmune data (late 2026), both with significant upside potential. Competitive pressures, funding needs beyond 2027, and uncertain commercial uptake in cell therapy remain material risks for AUTL. Read the full article on Seeking AlphaAnalyse-artikel • Feb 03
The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%
Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders won't be pleased to see that the share price has had a very rough...Analyse-artikel • Dec 20
Autolus Therapeutics plc's (NASDAQ:AUTL) Shares Bounce 28% But Its Business Still Trails The Industry
Autolus Therapeutics plc ( NASDAQ:AUTL ) shares have had a really impressive month, gaining 28% after a shaky period...Nieuw narratief • Aug 17
Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
Key Takeaways Accelerating adoption, regulatory progress, and expanded clinical indications position Autolus for increased market share and long-term revenue growth in advanced cancer therapies. Improved manufacturing efficiency and financial discipline strengthen margins, enabling investment in innovation and geographic expansion while supporting sustained profitability.Analyse-artikel • Apr 04
Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%
Celebrations may be in order for Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders, with the analysts delivering a...Seeking Alpha • Mar 04
Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Summary Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success. Despite the competitive landscape, AUTL's broad pipeline and recent approval of obe-cel position it well for future growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Autolus Therapeutics Will Remain Depressed For A While
Summary Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism. Despite initial stock surge post-approval, AUTL's stock has steadily declined due to market skepticism on CAR-T's financial efficiency and pre-approval fundraising. AUTL's financials show a strong cash position but poor market performance, with the stock trading below cash value, excluding debt. The market demands sustained earnings and cautious fund-raising, suggesting AUTL's stock will remain depressed for the next 3-4 years. Read the full article on Seeking AlphaAnalyse-artikel • Jan 07
Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Nov 21
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Summary Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company’s Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash runway of 1.9 years and no financial debt provide a solid financial foundation to support AUCATZYL's commercialization and future growth. Key risks include scaling manufacturing, securing insurance coverage, and expanding treatment centers, but these are manageable, supporting a bullish long-term outlook. Autolus's valuation appears undervalued given AUCATZYL's market potential and robust pipeline, including multiple CAR T-cell therapies in various trial stages. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Summary Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights. An intriguing secondary catalyst is obe-cel in autoimmune disease systemic lupus erythematosus - positive data could send the share price soaring. I have followed Autolus for some time, and my “buy” calls have not come off — but I remain optimistic there is a cell therapy player of note here and I am keeping the faith. Read the full article on Seeking AlphaAnalyse-artikel • Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jul 31
Autolus Therapeutics: Major Inflection Point On The Horizon
Summary Today, we are putting T cell developmental firm Autolus Therapeutics plc back in the spotlight for the first time in a year and a half. The company could garner its first FDA approval later this year, and recently signed an enhanced partnership arrangement with a large player in the biotech space. An updated analysis around Autolus Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 14
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
Summary Autolus Therapeutics now has years of operational runway after recent financing. Operating expenses are manageable, with numerous pipeline projects in the hopper. Autolus likely has an approved therapy on their hands, just waiting for the November action date to realize it. Read the full article on Seeking AlphaAnalyse-artikel • Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$280m |
| Mar 31 2026 | n/a | n/a | -US$289m |
| Dec 31 2025 | US$3m | US$674k | -US$288m |
| Sep 30 2025 | n/a | n/a | -US$225m |
| Jun 30 2025 | n/a | n/a | -US$228m |
| Mar 31 2025 | n/a | n/a | -US$238m |
| Dec 31 2024 | US$2m | US$595k | -US$221m |
| Sep 30 2024 | n/a | n/a | -US$270m |
| Jun 30 2024 | n/a | n/a | -US$234m |
| Mar 31 2024 | n/a | n/a | -US$221m |
| Dec 31 2023 | US$2m | US$551k | -US$208m |
| Sep 30 2023 | n/a | n/a | -US$158m |
| Jun 30 2023 | n/a | n/a | -US$155m |
| Mar 31 2023 | n/a | n/a | -US$152m |
| Dec 31 2022 | US$3m | US$502k | -US$149m |
| Sep 30 2022 | n/a | n/a | -US$164m |
| Jun 30 2022 | n/a | n/a | -US$155m |
| Mar 31 2022 | n/a | n/a | -US$146m |
| Dec 31 2021 | US$3m | US$543k | -US$142m |
| Sep 30 2021 | n/a | n/a | -US$143m |
| Jun 30 2021 | n/a | n/a | -US$147m |
| Mar 31 2021 | n/a | n/a | -US$145m |
| Dec 31 2020 | US$4m | US$522k | -US$142m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$127m |
| Dec 31 2019 | US$5m | US$517k | -US$124m |
Compensatie versus markt: De totale vergoeding ($USD 2.70M ) Chris } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.41M ).
Compensatie versus inkomsten: De vergoeding van Chris is gestegen terwijl het bedrijf verliesgevend is.
CEO
Chris Itin (62 yo)
10.4yrs
Tenure
US$2,698,699
Compensatie
Dr. Christian Martin Itin, also known as Chris, Ph D., has been the Chief Executive Officer of Autolus Therapeutics Plc. (Former Name: Autolus Limited) since March 3, 2016.Dr. Itin has been Director of Au...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 10.4yrs | US$2.70m | 0.42% $ 2.4m | |
| Founder | 12yrs | geen gegevens | 0% $ 0 | |
| Senior VP & CFO | 3yrs | geen gegevens | 0% $ 0 | |
| Senior VP & COO | 9.8yrs | geen gegevens | 0.072% $ 413.3k | |
| Senior VP of Finance | less than a year | geen gegevens | geen gegevens | |
| Senior VP & Chief Technology Officer | less than a year | geen gegevens | 0.0089% $ 51.0k | |
| Senior VP of Legal Affairs & General Counsel and Secretary | 4.8yrs | geen gegevens | 0.0069% $ 39.6k | |
| Senior VP & Chief Human Resources Officer | 4.8yrs | geen gegevens | 0% $ 0 | |
| Senior VP & Chief Business Development Officer | 2.6yrs | geen gegevens | 0.0031% $ 17.6k | |
| Senior VP & Chief Development Officer | 1.9yrs | geen gegevens | geen gegevens | |
| Senior VP | less than a year | geen gegevens | geen gegevens | |
| Director of Investor Relations | no data | geen gegevens | geen gegevens |
3.0yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AUTL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 11.8yrs | US$2.70m | 0.42% $ 2.4m | |
| Independent Non-Executive Director | 4.8yrs | US$201.61k | 0% $ 0 | |
| Independent Chairman of the Board | 2.3yrs | US$372.57k | 0% $ 0 | |
| Independent Non-Executive Director | 8.2yrs | US$200.48k | 0.0038% $ 21.5k | |
| Independent Non-Executive Director | 8.2yrs | US$207.90k | 0% $ 0 | |
| Independent Non-Executive Director | 2.6yrs | US$297.60k | 0% $ 0 | |
| Independent Non-Executive Director | 3.2yrs | US$198.91k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$13.45k | geen gegevens | |
| Independent Non-Executive Director | 2.3yrs | US$292.94k | 0% $ 0 | |
| Independent Non-Executive Director | 2.7yrs | US$269.16k | 0% $ 0 |
2.9yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AUTL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/17 16:57 |
| Aandelenkoers aan het einde van de dag | 2026/08/14 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Autolus Therapeutics plc wordt gevolgd door 17 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| James Shin | Deutsche Bank |
| Rajan Sharma | Goldman Sachs |
| Emily Bodnar | H.C. Wainwright & Co. |